Sanofi (EPA:SAN) has been given a €78.00 ($92.86) price target by equities research analysts at S&P Global in a note issued to investors on Tuesday. The brokerage presently has a “neutral” rating on the stock. S&P Global’s price objective suggests a potential upside of 9.60% from the company’s current price.
SAN has been the topic of several other research reports. Morgan Stanley set a €92.00 ($109.52) price target on shares of Sanofi and gave the stock a “buy” rating in a research report on Friday, October 6th. Goldman Sachs Group set a €82.00 ($97.62) price target on shares of Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Berenberg Bank set a €97.00 ($115.48) price target on shares of Sanofi and gave the stock a “neutral” rating in a research report on Monday. Deutsche Bank set a €93.00 ($110.71) price target on shares of Sanofi and gave the stock a “buy” rating in a research report on Friday. Finally, Barclays set a €65.00 ($77.38) price target on shares of Sanofi and gave the stock a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of €85.94 ($102.31).
Sanofi (EPA:SAN) opened at €71.17 ($84.73) on Tuesday. The stock has a market cap of $89,900.00 and a PE ratio of 19.71. Sanofi has a 52-week low of €70.09 ($83.44) and a 52-week high of €92.97 ($110.68).
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.